Completed PHASE1 INTERVENTIONAL 3-arm NCT01324752

A Drug-Drug Interaction Study of Losartan and PA21

A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults

Sponsor: Vifor Pharma

Conditions Drug Interaction Potentiation

Interventions No PA21; Losartan with food PA21 and Losartan with Food PA21 with food and Losartan 2 hours later

Updated 8 times since 2017 Last updated: Dec 19, 2012 Started: Mar 31, 2011 Primary completion: Jun 30, 2011 Completion: Jun 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Drug Interaction Potentiation and is currently completed. Vifor Pharma leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Oct 2021 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — Oct 2021 [monthly]

Completed PHASE1
May 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jun 2018 — May 2020 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Mar 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vifor Pharma

Data source: Vifor Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Anaheim, United States